Epidemiology Data Slicer – Type 2 Diabetes
The oral type 2 diabetes (T2D) drug market is expected to grow, fueled by rising prevalence and an increasing aging population. Owing to the risk of proteinuria, cardiovascular (CV) complications,…
Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of…
The highly genericized biguanides and sulfonylureas are, by far, the most heavily prescribed type 2 diabetes (T2D) drug classes. However, branded agents from several drug classes are jostling for…
The type 2 diabetes (T2D) therapy market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to…
MARKET OUTLOOK Type 2 diabetes (T2D) has an extremely high prevalence in the top five European markets (France, Germany, Italy, Spain, UK). Low-cost metformin (Merck KgaA’s Glucophage, generics)…